A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines
Latest Information Update: 15 Dec 2022
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allergan
- 09 Dec 2022 Status changed from active, no longer recruiting to completed.
- 03 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2021 New trial record